Alessandra DallAcqua
Overview
Explore the profile of Alessandra DallAcqua including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pellarin I, DallAcqua A, Favero A, Segatto I, Rossi V, Crestan N, et al.
Signal Transduct Target Ther
. 2025 Jan;
10(1):11.
PMID: 39800748
Cyclin Dependent Kinases (CDKs) are closely connected to the regulation of cell cycle progression, having been first identified as the kinases able to drive cell division. In reality, the human...
2.
Segatto I, Mattevi M, Rampioni Vinciguerra G, Crestan N, Musco L, Favero A, et al.
J Pathol
. 2024 Oct;
264(4):434-447.
PMID: 39449657
Breast cancer (BC) is marked by significant genetic, morphological and clinical heterogeneity. To capture this heterogeneity and unravel the molecular mechanisms driving tumor progression and drug resistance, we established a...
3.
Favero A, Segatto I, Capuano A, Mattevi M, Rampioni Vinciguerra G, Musco L, et al.
NPJ Breast Cancer
. 2024 Jan;
10(1):5.
PMID: 38184660
The extracellular matrix (ECM) is an important component of the tumor microenvironment and undergoes extensive remodeling during both initiation and progression of breast cancer (BC). EMILIN1 is an ECM glycoprotein,...
4.
Segatto I, Rampioni Vinciguerra G, Pellarin I, DallAcqua A, Berton S, Citron F, et al.
Cancer Commun (Lond)
. 2023 Jun;
43(7):844-849.
PMID: 37337406
No abstract available.
5.
Rampioni Vinciguerra G, Sonego M, Segatto I, DallAcqua A, Vecchione A, Baldassarre G, et al.
Front Oncol
. 2022 Jun;
12:891580.
PMID: 35712501
The cyclin D-CDK4/6 complexes play a pivotal role in controlling the cell cycle. Deregulation in cyclin D-CDK4/6 pathway has been described in many types of cancer and it invariably leads...
6.
Rampioni Vinciguerra G, DallAcqua A, Segatto I, Mattevi M, Russo F, Favero A, et al.
Cell Death Dis
. 2021 Oct;
12(10):951.
PMID: 34654798
In colorectal cancer, mutation of KRAS (RAS) reduces therapeutic options, negatively affecting prognosis of the patients. In this setting, administration of CDK4/6-inhibitors, alone or in combination with other drugs, is...
7.
DallAcqua A, Bartoletti M, Masoudi-Khoram N, Sorio R, Puglisi F, Belletti B, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34204543
Alterations in components of the cell-cycle machinery are present in essentially all tumor types. In particular, molecular alterations resulting in dysregulation of the G1 to S phase transition have been...
8.
Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra G, DallAcqua A, et al.
J Pathol
. 2020 Nov;
253(2):234-245.
PMID: 33140857
The CDKN1B gene, encoding for the CDK inhibitor p27 , is mutated in defined human cancer subtypes, including breast, prostate carcinomas and small intestine neuroendocrine tumors. Lessons learned from small...
9.
Ranzuglia V, Lorenzon I, Pellarin I, Sonego M, DallAcqua A, DAndrea S, et al.
Oncogene
. 2020 Aug;
39(40):6370-6386.
PMID: 32848212
For many tumor types chemotherapy still represents the therapy of choice and many standard treatments are based on the use of platinum (PT) drugs. However, de novo or acquired resistance...
10.
Pellarin I, DallAcqua A, Gambelli A, Pellizzari I, DAndrea S, Sonego M, et al.
Oncogene
. 2020 Apr;
39(22):4390-4403.
PMID: 32332923
In epithelial ovarian cancer (EOC), response to platinum (PT)-based chemotherapy dictates subsequent treatments and predicts patients' prognosis. Alternative splicing is often deregulated in human cancers and can be altered by...